Raymond James on Regeneron Pharma (REGN): 'New Survey Indicates 1Q26 Uptick for Eylea HD, More to Come'
Tweet Send to a Friend
Raymond James analyst Chris Raymond reiterated an Outperform rating and $910.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
